News
MXCT
0.6956
-2.59%
-0.0185
Balanced Hold on MaxCyte: Weighing Repeated Revenue Misses and Soft 2026 Outlook Against Strong Cash Position and Emerging Platform Upside
TipRanks · 4h ago
Weekly Report: what happened at MXCT last week (0330-0403)?
Weekly Report · 1d ago
MaxCyte grants CFO Parmeet Ahuja 375,000 stock options under inducement plan
Reuters · 6d ago
MAXCYTE REPORTS INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4)
Reuters · 6d ago
Analysts Offer Insights on Healthcare Companies: MoonLake Immunotherapeutics (MLTX), AbSci (ABSI) and MaxCyte (MXCT)
TipRanks · 03/30 11:02
Weekly Report: what happened at MXCT last week (0323-0327)?
Weekly Report · 03/30 09:17
MaxCyte Appoints New Chief Financial Officer Ahuja
TipRanks · 03/27 22:10
MaxCyte appoints Parmeet Ahuja CFO effective March 30, 2026; Douglas Swirsky transitions from the role
Reuters · 03/27 20:55
MaxCyte Faces Nasdaq Delisting Risk as Share Price Slump Threatens Liquidity and Capital Access
TipRanks · 03/27 06:00
MaxCyte Earnings Call Weighs Short‑Term Pain, Long‑Term Upside
TipRanks · 03/27 00:18
MaxCyte Price Target Cut to $5.00/Share From $7.00 by Craig-Hallum
Dow Jones · 03/25 16:34
MaxCyte Is Maintained at Buy by Craig-Hallum
Dow Jones · 03/25 16:34
Craig-Hallum Maintains Buy on MaxCyte, Lowers Price Target to $5
Benzinga · 03/25 16:24
MaxCyte price target lowered to $5 from $7 at Craig-Hallum
TipRanks · 03/25 13:41
MaxCyte outlines $30M–$32M 2026 revenue target as ExPERT DTx launch and SPL milestones drive outlook
Seeking Alpha · 03/25 06:15
MaxCyte (MXCT) Q4 2025 Earnings Call Transcript
The Motley Fool · 03/24 21:49
MaxCyte, Inc. (MXCT) Reports Q4 Loss, Misses Revenue Estimates
NASDAQ · 03/24 21:35
MaxCyte Reports Lower 2025 Revenue, Provides 2026 Outlook
TipRanks · 03/24 20:55
MaxCyte sees FY26 revenue $30M-$32M, consensus $38.41M
TipRanks · 03/24 20:22
MAXCYTE INC: Q4 EPS $-0.09 - SEC FILING
Reuters · 03/24 20:17
More
Webull provides a variety of real-time MXCT stock news. You can receive the latest news about Maxcyte through multiple platforms. This information may help you make smarter investment decisions.
About MXCT
MaxCyte, Inc. is a commercial cell engineering company. The Company is focused on providing enabling platform technologies to advance the discovery, development and commercialization of cell therapeutics, including cell and gene therapies, and to support cell-based research and development. It has developed and commercialized its proprietary Flow Electroporation technology, which is used by biopharmaceutical companies in the complex engineering of a variety of cells. Its ExPERT platform is based on its Flow Electroporation technology, which has been designed to address this rapidly expanding cell therapy market and can be utilized across the continuum of the cell therapy sector, from discovery and development through commercialization of cell-based medicines. The ExPERT family of products includes four instruments, which are known as the ATx, STx, GTx and VLx, as well as a portfolio of proprietary related disposables and consumables.